Join the Benign Prostatic Hyperplasia (BPH) group to help and get support from people like you.
Benign Prostatic Hyperplasia (BPH) News
Related terms: Benign Prostatic Enlargement, Benign Prostatic Hypertrophy (BPH), Enlarged prostate, Prostate, enlarged, BPH, Benign Prostatic Hypertrophy
Blue Laser Vaporization Effective for Benign Prostatic Hyperplasia
TUESDAY, April 8, 2025 – Blue laser vaporization alleviates lower urinary tract symptoms while preserving sexual function in patients undergoing benign prostatic hyperplasia (BPH) surgery, according...
Aquablation Appears to Be Safe, Effective for Enlarged Prostates
TUESDAY, March 25, 2025 – The Aquablation water-based surgical procedure is safe and effective for use with enlarged prostates compared with laser surgery, according to a study presented at the 40th...
HoLEP Double-n Technology Promising for Benign Prostatic Hyperplasia
THURSDAY, Feb. 6, 2025 – For men with benign prostatic hyperplasia (BPH), transurethral Holmium Laser of the Prostate (HoLEP) with Double-n Technology shows promise for improving urinary symptoms...
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
THURSDAY, Jan. 2, 2025 – Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign...
Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
MARLBOROUGH, Mass., Dec. 23, 2024 /PRNewswire/ – Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved Gemtesa (vibegron), a beta-3 (β3) ...
Comparable Results Seen for HoLEP With, Without Preservation of Urethral Mucosa in BPH
THURSDAY, Dec. 5, 2024 – For patients with benign prostatic hyperplasia (BPH), holmium laser enucleation of the prostate (HoLEP) with preservation of the urethral mucosa from bladder neck to the tip...
Prostatic Artery Embolization Offers Lasting Benefit for BPH
THURSDAY, Oct. 3, 2024 – For men with benign prostatic hyperplasia (BPH), prostatic artery embolization (PAE) is safe and effective over 24 months of follow-up, according to a study published online...
Surgical Techniques Compared for ThuLEP for Benign Prostatic Hyperplasia
TUESDAY, Aug. 6, 2024 – For patients undergoing Thulium laser enucleation of the prostate (ThuLEP) for benign prostatic hyperplasia (BPH), there are no significant differences in intraoperative and...
Certain Prostate Meds Might Help Prevent Dementia
WEDNESDAY, June 20, 2024 – Prostate medications might help reduce the risk of a specific type of dementia, a new study suggests. People were less likely to develop Lewy body dementia when taking...
Aquablation, HoLEP Provide Unique Benefits for Men With Benign Prostate Hyperplasia
TUESDAY, June 4, 2024 – For men with benign prostate hyperplasia, aquablation provides temporary benefits for ejaculation and continence at three months, while holmium laser enucleation of the...
FDA Approves Entadfi (finasteride and tadalafil) as a New Treatment for Benign Prostatic Hyperplasia
MIAMI, Dec. 13, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, a...
FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
October 6, 2011 – The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate...
FDA Medwatch Alert: U-Prosta: Undeclared Drug Ingredient
ISSUE: USA Far Ocean Group, Inc. issues voluntary nationwide recall of U-Prosta, a product marketed as a dietary supplement that contains undeclared terazosin hydrochloride. Lab analysis by FDA of ...
FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate
June 14, 2010 - GlaxoSmithKline announced today the U.S. Food and Drug Administration (FDA) has approved Jalyn, a single-capsule combination of dutasteride (0.5 mg) and tamsulosin (0.4 mg) to treat...
Further information
Related condition support groups
Related drug support groups
Cialis, Flomax, tamsulosin, tadalafil, finasteride, prazosin